New drugs targeting Alzheimer's disease
Official title: Novel brain-penetrant drugs for translation-targeting therapeutics of Alzheimer’s disease
Funded at Transchromix, LLC. · NIH-10821732 · Data updated 2026-11-12
This study is exploring a new drug that could help treat Alzheimer's disease by targeting a specific enzyme in the brain, with the hope of improving memory and thinking skills in people affected by this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Transchromix, LLC. NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $497,218 |
| NIH project number | 1R41AG085859-01 |
| Project ID | NIH-10821732 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those in mid to late stages of the condition.
✕Less likely to help
Patients with early-stage Alzheimer's or other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on developing innovative drugs that can penetrate the brain to treat Alzheimer's disease, a condition that leads to memory loss and cognitive decline. The approach involves understanding the role of a specific enzyme, G9a, in the disease's progression and using a drug called MS1262 to inhibit its activity. By doing so, the researchers aim to reverse harmful changes in brain proteins associated with cognitive functions and restore normal behavior in animal models. The project is a collaboration between TransChromix, LLC and the UNC School of Medicine.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that significantly improve cognitive and emotional functions in Alzheimer's patients.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting G9a in Alzheimer's models, indicating potential for success.
Where this research is happening
-
Transchromix, LLC.
Chapel Hill, United States Active
Researchers
- Principal investigator: Chen, Xian — Transchromix, LLC.
- Study coordinator: Chen, Xian
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.